Clinical Stage Biotech Stocks
Biopharmaceutical entities in this cohort focus on the high-risk transition from laboratory discovery to human efficacy trials, operating primarily as research and development engines without commercialized product revenue.
As of Oct 23, 2026, Clinical Stage Biotech has 448 US-listed companies worth $365B combined. The median member moved +1.3% over the past week; SYRE led among the 25 largest at +13.1% and RGC trailed at -20.0%.
Companies in Clinical Stage Biotech
- RVMD – Revolution Medicines Inc, $40.2B
- EXEL – Exelixis Inc, $16.2B
- BBIO – BridgeBio Pharma Inc, $13.4B
- SMMT – Summit Therapeutics PLC, $12.3B
- PCVX – Vaxcyte Inc, $9.9B
- KYMR – Kymera Therapeutics Inc, $9.3B
- SYRE – Spyre Therapeutics Inc., $8.7B
- ABVX – Abivax SA American Depositary Shares, $7.7B
- KNSA – Kiniksa Pharmaceuticals Ltd, $6.3B
- IMVT – Immunovant Inc, $5.9B
- BLTE – Belite Bio Inc ADR, $5.8B
- COGT – Cogent Biosciences Inc, $5.5B
- KOD – Kodiak Sciences Inc, $5.4B
- ORKA – Oruka Therapeutics, Inc., $5.2B
- ERAS – Erasca Inc, $5.1B
- RGC – Regencell Bioscience Holdings Ltd, $4.8B
- TNGX – Tango Therapeutics Inc, $4.5B
- DFTX – Definium Therapeutics, Inc., $4.4B
- EWTX – Edgewise Therapeutics Inc, $4.3B
- DNTH – Dianthus Therapeutics Inc., $4.3B
- RLAY – Relay Therapeutics Inc, $4B
- ABCL – Abcellera Biologics Inc, $3.8B
- AMLX – Amylyx Pharmaceuticals Inc, $3.6B
- XENE – Xenon Pharmaceuticals Inc, $3.5B
- IDYA – Ideaya Biosciences Inc, $3.5B
- CELC – Celcuity LLC, $3.2B
- PBLS – Parabilis Medicines, Inc. Common Stock, $3.1B
- IRON – Disc Medicine Inc., $3B
- DNLI – Denali Therapeutics Inc, $3B
- DYN – Dyne Therapeutics Inc, $2.9B
- ELVN – Enliven Therapeutics Inc., $2.9B
- NRIX – Nurix Therapeutics Inc, $2.9B
- RCUS – Arcus Biosciences Inc, $2.8B
- VRDN – Viridian Therapeutics Inc, $2.5B
- BEAM – Beam Therapeutics Inc, $2.5B
- MBX – MBX Biosciences, Inc. Common Stock, $2.5B
- NAMS – NewAmsterdam Pharma Company N.V. Ordinary Shares, $2.4B
- CLDX – Celldex Therapeutics Inc, $2.3B
- SLS – Sellas Life Sciences Group Inc, $2.3B
- VERA – Vera Therapeutics Inc, $2.2B
- IMNM – Immunome Inc, $2.1B
- ZYME – Zymeworks Inc. Common Stock, $1.9B
- RXRX – Recursion Pharmaceuticals Inc, $1.9B
- MLYS – Mineralys Therapeutics, Inc. Common Stock, $1.9B
- XNCR – Xencor Inc, $1.9B
- GENB – Generate Biomedicines, Inc. Common Stock, $1.8B
- SEPN – Septerna, Inc. Common Stock, $1.8B
- ZBIO – Zenas BioPharma, Inc. Common Stock, $1.8B
- TRVI – Trevi Therapeutics Inc, $1.8B
- VIR – Vir Biotechnology Inc, $1.8B
- BHVN – Biohaven Ltd., $1.8B
- PVLA – Palvella Therapeutics, Inc, $1.7B
- KLRA – Kailera Therapeutics, Inc. Common Stock, $1.7B
- COAG – Hemab Therapeutics Holdings, Inc. Common Stock, $1.7B
- NBTX – Nanobiotix, $1.7B
- STOK – Stoke Therapeutics Inc, $1.7B
- GPCR – Structure Therapeutics Inc. American Depositary Shares, $1.6B
- NTLA – Intellia Therapeutics Inc, $1.6B
- QURE – Uniqure NV, $1.6B
- CMPS – Compass Pathways Plc, $1.6B
- KRSA – Korsana Biosciences, Inc., $1.5B
- MAZE – Maze Therapeutics, Inc. Common Stock, $1.5B
- TYRA – Tyra Biosciences Inc, $1.5B
- ABSI – Absci Corp, $1.5B
- INBX – Inhibrx Biosciences, Inc., $1.4B
- TSHA – Taysha Gene Therapies Inc, $1.4B
- AAPG – Ascentage Pharma Group International, $1.4B
- RAPP – Rapport Therapeutics, Inc. Common Stock, $1.3B
- DRTS – Alpha Tau Medical Ltd, $1.3B
- REPL – Replimune Group Inc, $1.3B
- ORIC – Oric Pharmaceuticals Inc, $1.2B
- TRAX – First Tracks Biotherapeutics, $1.2B
- KARD – Kardigan, Inc. Common Stock, $1.2B
- LBRX – LB Pharmaceuticals Inc Common Stock, $1.2B
- VOR – Vor Biopharma Inc, $1.2B
- OMER – Omeros Corporation, $1.2B
- BCAX – Bicara Therapeutics Inc. Common Stock, $1.2B
- DMRA – Damora Therapeutics, Inc., $1.2B
- JANX – Janux Therapeutics Inc, $1.1B
- LTGO – Latigo Biotherapeutics, Inc. Common Stock, $1.1B
- IMTX – Immatics NV, $1B
- ANL – Adlai Nortye Ltd. American Depositary Shares, $999M
- CGEM – Cullinan Oncology LLC, $961M
- ANRO – Alto Neuroscience, Inc., $956M
- MGTX – MeiraGTx Holdings PLC, $955M
- AKTS – Aktis Oncology, Inc. Common stock, $890M
- ALMS – Alumis Inc, $885M
- CRVS – Corvus Pharmaceuticals Inc, $876M
- SLBT – SL Science Holding Limited Ordinary Shares, $869M
- JBIO – Jade Biosciences, Inc., $853M
- GLUE – Monte Rosa Therapeutics Inc, $839M
- SANA – Sana Biotechnology Inc, $835M
- AVBP – ArriVent BioPharma, Inc. Common Stock, $821M
- MLTX – MoonLake Immunotherapeutics, $813M
- HELP – Cybin Inc., $799M
- SGP – SpyGlass Pharma, Inc., $792M
- APMD – Apnimed, Inc. Common Stock, $771M
- IVA – Inventiva Sa, $770M
- WVE – Wave Life Sciences Ltd, $745M
- SLDB – Solid Biosciences LLC, $737M
- FTH – Faeth Therapeutics, Inc., $733M
- DSGN – Design Therapeutics Inc, $732M
- ACHV – Achieve Life Sciences Inc, $729M
- AVTX – Avalo Therapeutics Inc, $728M
- NVCT – Nuvectis Pharma Inc, $716M
- FDMT – 4D Molecular Therapeutics Inc, $711M
- CADL – Candel Therapeutics Inc, $709M
- PRME – Prime Medicine, Inc. Common Stock, $707M
- PROK – ProKidney Corp., $695M
- OLMA – Olema Pharmaceuticals Inc, $684M
- AURA – Aura Biosciences Inc, $678M
- DBVT – DBV Technologies, $663M
- SLN – Silence Therapeutics PLC, $613M
- CLYM – Climb Bio Inc, $592M
- FLGT – Fulgent Genetics Inc, $591M
- CTMX – CytomX Therapeutics Inc, $556M
- ETRA – Electra Therapeutics, Inc. Common stock, $549M
- STTK – Shattuck Labs Inc, $548M
- CBIO – Crescent Biopharma, Inc., $532M
- DRUG – Bright Minds Biosciences Inc, $506M
- ALLO – Allogene Therapeutics Inc, $504M
- MNPR – Monopar Therapeutics Inc, $498M
- EPRX – Eupraxia Pharmaceuticals Inc. Common Stock, $493M
- ACRS – Aclaris Therapeutics Inc, $483M
- YDES – YD Bio Ltd, $477M
- RGNX – Regenxbio Inc, $473M
- ARVN – Arvinas Inc, $472M
- OCS – Oculis Holding AG Ordinary shares, $461M
- MPLT – MapLight Therapeutics, Inc. Common Stock, $458M
- BLSM – BlossomHill Therapeutics, Inc. Common Stock, $458M
- DMAC – DiaMedica Therapeutics Inc, $449M
- EDIT – Editas Medicine Inc, $445M
- TECX – Tectonic Therapeutic, Inc., $444M
- OVID – Ovid Therapeutics Inc, $441M
- PRTA – Prothena Corporation plc, $435M
- ENTX – Entera Bio Ltd, $435M
- NGNE – Neurogene Inc, $431M
- ASMB – Assembly Biosciences Inc, $409M
- EIKN – Eikon Therapeutics, Inc. Common Stock, $408M
- ZURA – Zura Bio Limited Class A Ordinary Shares, $396M
- KYTX – Kyverna Therapeutics, Inc. Common Stock, $395M
- CAPR – Capricor Therapeutics Inc, $384M
- TRXB – TRex Bio, Inc. Common stock, $384M
- SCTX – Scribe Therapeutics Inc. Common Stock, $380M
- INDP – Indaptus Therapeutics Inc, $380M
- GALT – Galectin Therapeutics Inc, $374M
- ENTA – Enanta Pharmaceuticals Inc, $352M
- RLMD – Relmada Therapeutics Inc, $347M
- TTRX – Turn Therapeutics Inc. Common Stock, $337M
- BNTC – Benitec Biopharma Ltd ADR, $335M
- ARTV – Artiva Biotherapeutics, Inc. Common Stock, $332M
- CCCC – C4 Therapeutics Inc, $325M
- IRD – Opus Genetics, Inc., $318M
- CYPH – Cypherpunk Technologies Inc., $299M
- FULC – Fulcrum Therapeutics Inc, $279M
- SRZN – Surrozen Inc, $276M
- AGEN – Agenus Inc, $273M
- CTNM – Contineum Therapeutics, Inc. Class A Common Stock, $266M
- BBOT – BridgeBio Oncology Therapeutics, Inc., $265M
- OCGN – Ocugen Inc, $265M
- SABS – SAB Biotherapeutics Inc, $262M
- CATX – Perspective Therapeutics Inc., $259M
- PRLD – Prelude Therapeutics Inc, $258M
- ACIU – AC Immune Ltd, $256M
- IMRX – Immuneering Corp, $255M
- LCTX – Lineage Cell Therapeutics Inc, $251M
- IKT – Inhibikase Therapeutics Inc, $251M
- PALI – Palisade Bio Inc, $251M
- CABA – Cabaletta Bio Inc, $251M
- IPSC – Century Therapeutics Inc, $250M
- BCYC – Bicycle Therapeutics Ltd, $245M
- RCKT – Rocket Pharmaceuticals Inc, $239M
- QTTB – Q32 Bio Inc, $232M
- FATE – Fate Therapeutics Inc, $231M
- SLGL – Sol Gel Technologies Ltd, $227M
- GLSI – Greenwich Lifesciences Inc, $226M
- LRMR – Larimar Therapeutics Inc, $224M
- KROS – Keros Therapeutics Inc, $222M
- BIOA – BioAge Labs, Inc, $222M
- PYXS – Pyxis Oncology Inc, $220M
- CGEN – Compugen, $219M
- MGNX – MacroGenics Inc, $218M
- LXEO – Lexeo Therapeutics, Inc. Common Stock, $217M
- VOGX – Vogenx Inc Common Stock, $216M
- CAMP – CAMP4 THERAPEUTICS CORPORATION, $215M
- ALEC – Alector Inc, $214M
- LYEL – Lyell Immunopharma Inc, $213M
- TRDA – Entrada Therapeutics Inc, $209M
- ZNTL – Zentalis Pharmaceuticals Llc, $209M
- RNAC – Cartesian Therapeutics Inc., $202M
- PRQR – ProQR Therapeutics BV, $195M
- WHWK – Whitehawk Therapeutics, Inc., $194M
- ELDN – Eledon Pharmaceuticals Inc, $190M
- EVMN – Evommune, Inc., $188M
- SION – Sionna Therapeutics, Inc. Common Stock, $187M
- STRO – Sutro Biopharma, $181M
- ALXO – Alx Oncology Holdings , $173M
- DTIL – Precision BioSciences Inc, $173M
- ANTX – AN2 Therapeutics Inc, $166M
- PEPG – PepGen Ltd, $166M
Showing the 200 largest of 448 members by market cap.